NZ720440B2 - Mammalian muscle-derived stem cells - Google Patents
Mammalian muscle-derived stem cells Download PDFInfo
- Publication number
- NZ720440B2 NZ720440B2 NZ720440A NZ72044014A NZ720440B2 NZ 720440 B2 NZ720440 B2 NZ 720440B2 NZ 720440 A NZ720440 A NZ 720440A NZ 72044014 A NZ72044014 A NZ 72044014A NZ 720440 B2 NZ720440 B2 NZ 720440B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- mscs
- mesenchymal stem
- mir
- stem cells
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 42
- 210000003205 Muscles Anatomy 0.000 title abstract description 25
- 210000004027 cells Anatomy 0.000 claims abstract description 209
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 claims abstract description 177
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims abstract description 42
- 101700078950 CD44 Proteins 0.000 claims abstract description 24
- 102100003735 CD44 Human genes 0.000 claims abstract description 24
- 102100008333 THY1 Human genes 0.000 claims abstract description 23
- 101700026084 THY1 Proteins 0.000 claims abstract description 23
- 210000001612 Chondrocytes Anatomy 0.000 claims abstract description 19
- 210000004409 Osteocytes Anatomy 0.000 claims abstract description 15
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 14
- 230000001114 myogenic Effects 0.000 claims abstract description 12
- 102100005499 PTPRC Human genes 0.000 claims abstract description 11
- 101700059076 PTPRC Proteins 0.000 claims abstract description 11
- 102100001478 ITGB1 Human genes 0.000 claims abstract description 10
- 101710006661 ITGB1 Proteins 0.000 claims abstract description 10
- 210000002889 Endothelial Cells Anatomy 0.000 claims abstract description 9
- 210000003494 Hepatocytes Anatomy 0.000 claims abstract description 9
- 210000003061 neural cell Anatomy 0.000 claims abstract description 9
- 230000000747 cardiac effect Effects 0.000 claims abstract description 8
- 239000002609 media Substances 0.000 claims description 43
- 230000004069 differentiation Effects 0.000 claims description 38
- 229920001239 microRNA Polymers 0.000 claims description 37
- 210000001519 tissues Anatomy 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 24
- 239000002679 microRNA Substances 0.000 claims description 24
- 241000283086 Equidae Species 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 17
- 150000002500 ions Chemical class 0.000 claims description 15
- 206010043255 Tendonitis Diseases 0.000 claims description 13
- 210000002435 Tendons Anatomy 0.000 claims description 13
- 230000002188 osteogenic Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000003041 Ligaments Anatomy 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000002648 chondrogenic Effects 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 206010003246 Arthritis Diseases 0.000 claims description 7
- 239000001963 growth media Substances 0.000 claims description 7
- 201000009859 osteochondrosis Diseases 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 230000002293 adipogenic Effects 0.000 claims description 6
- 230000000735 allogeneic Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000700198 Cavia Species 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 241000283898 Ovis Species 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 108010036395 Endoglin Proteins 0.000 claims description 3
- 230000003511 endothelial Effects 0.000 claims description 3
- 230000001537 neural Effects 0.000 claims description 3
- 102000012085 Endoglin Human genes 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 229940035295 Ting Drugs 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 102100009705 ENG Human genes 0.000 abstract description 27
- 101710004859 ENG Proteins 0.000 abstract description 27
- 238000000034 method Methods 0.000 abstract description 25
- 241000283073 Equus caballus Species 0.000 description 58
- 210000001185 Bone Marrow Anatomy 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 210000001744 T-Lymphocytes Anatomy 0.000 description 16
- 235000015110 jellies Nutrition 0.000 description 16
- 239000008274 jelly Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000003387 muscular Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 9
- 108090001123 antibodies Proteins 0.000 description 9
- 210000000988 Bone and Bones Anatomy 0.000 description 8
- 230000003902 lesions Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 229920002864 Mir-218 microRNA precursor family Polymers 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229960005069 Calcium Drugs 0.000 description 6
- 210000003194 Forelimb Anatomy 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- -1 HUTCH-l Proteins 0.000 description 5
- 108020004388 MicroRNAs Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000002522 swelling Effects 0.000 description 5
- 210000003414 Extremities Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 4
- 210000003141 Lower Extremity Anatomy 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 230000001413 cellular Effects 0.000 description 4
- 230000003021 clonogenic Effects 0.000 description 4
- 238000010192 crystallographic characterization Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000877 morphologic Effects 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 230000000399 orthopedic Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- KDXHLJMVLXJXCW-UHFFFAOYSA-J Alcian blue stain Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cu+2].[N-]1C(N=C2C3=CC(CSC(N(C)C)=[N+](C)C)=CC=C3C(N=C3C4=CC=C(CSC(N(C)C)=[N+](C)C)C=C4C(=N4)[N-]3)=N2)=C(C=C(CSC(N(C)C)=[N+](C)C)C=C2)C2=C1N=C1C2=CC(CSC(N(C)C)=[N+](C)C)=CC=C2C4=N1 KDXHLJMVLXJXCW-UHFFFAOYSA-J 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 3
- 210000002805 Bone Matrix Anatomy 0.000 description 3
- 210000000845 Cartilage Anatomy 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 229920002676 Complementary DNA Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241001272567 Hominoidea Species 0.000 description 3
- 229920001850 Nucleic acid sequence Polymers 0.000 description 3
- 229940049954 Penicillin Drugs 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000014961 Protein Precursors Human genes 0.000 description 3
- 108010078762 Protein Precursors Proteins 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 230000001058 adult Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229960000626 benzylpenicillin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000002519 immonomodulatory Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004962 mammalian cells Anatomy 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 230000001172 regenerating Effects 0.000 description 3
- 238000003559 rna-seq method Methods 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 206010061728 Bone lesion Diseases 0.000 description 2
- 102100016492 CD34 Human genes 0.000 description 2
- 108060001251 CD34 Proteins 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- VDABVNMGKGUPEY-UHFFFAOYSA-N Carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 241000243321 Cnidaria Species 0.000 description 2
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 2
- 210000004700 Fetal Blood Anatomy 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 208000009883 Joint Disease Diseases 0.000 description 2
- 210000001503 Joints Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 206010073713 Musculoskeletal injury Diseases 0.000 description 2
- 210000002356 Skeleton Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000001562 Sternum Anatomy 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960003942 amphotericin B Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial Effects 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- 230000000975 bioactive Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000001332 colony forming Effects 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 210000004748 cultured cells Anatomy 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003412 degenerative Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000002241 glass-ceramic Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 230000003256 osteocytic Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000002700 transcriptomic Methods 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-azaniumyl-7-oxononanoate Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 102100005377 BMP2 Human genes 0.000 description 1
- 101700000123 BMP2 Proteins 0.000 description 1
- 102100015886 BMP4 Human genes 0.000 description 1
- 101700005069 BMP4 Proteins 0.000 description 1
- 102100015882 BMP7 Human genes 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 229940112869 Bone morphogenetic proteins Drugs 0.000 description 1
- 102100003268 CD14 Human genes 0.000 description 1
- 101700027514 CD14 Proteins 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102000027998 CD44 antigen Human genes 0.000 description 1
- 108091015735 CD44 antigen Proteins 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 210000004439 Collateral Ligaments Anatomy 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229960000789 Guanidine Hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 210000003692 Ilium Anatomy 0.000 description 1
- 102400000705 Intracellular domain 2 Human genes 0.000 description 1
- 101800001556 Intracellular domain 2 Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102100006043 MCAM Human genes 0.000 description 1
- 101710034704 MCAM Proteins 0.000 description 1
- 108060001639 MOCOS Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 210000003716 Mesoderm Anatomy 0.000 description 1
- 201000001861 Miles-Carpenter syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000004683 Myoblasts, Skeletal Anatomy 0.000 description 1
- 101710039712 NT5E Proteins 0.000 description 1
- 102100017063 NT5E Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102100010691 SMCP Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 210000002536 Stromal Cells Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 108010031650 Thy-1 Antigens Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000003954 Umbilical Cord Anatomy 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agents Drugs 0.000 description 1
- 230000001857 anti-mycotic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940095629 edetate calcium disodium Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 108010036236 extracellular matrix receptor Proteins 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 108060004131 ispF Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003137 locomotive Effects 0.000 description 1
- 102000027675 major histocompatibility complex family Human genes 0.000 description 1
- 108091007937 major histocompatibility complex family Proteins 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000006956 minimum essential medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003349 osteoarthritic Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 230000001582 osteoblastic Effects 0.000 description 1
- 230000002138 osteoinductive Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004017 serum-free culture media Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2R,3R,4S,5S,6R)-2-[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010456 wollastonite Substances 0.000 description 1
- 229910052882 wollastonite Inorganic materials 0.000 description 1
- 200000000019 wound Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
Abstract
The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of MSCs that can differentiate into different cell lineages. The MSCs obtained by the method express CD105, CD44, CD90, and either miR-128 or miR-133B, do not express CD45, MHC II, CD29 and miR-656, and are capable of being being differentiated into adipocytes, osteocytes, chondrocytes, myogenic cells, endothelial cells, neural cells, cardiac cells, and hepatocytes. he method express CD105, CD44, CD90, and either miR-128 or miR-133B, do not express CD45, MHC II, CD29 and miR-656, and are capable of being being differentiated into adipocytes, osteocytes, chondrocytes, myogenic cells, endothelial cells, neural cells, cardiac cells, and hepatocytes.
Description
MAMMALIAN MUSCLE-DERIVED STEM CELLS
FIELD OF THE INVENTION
The invention relates to the tion of mammalian stem cells derived from muscular tissue
and uses ofsuch stem cells in treating injured tissue. More particularly, the invention provides
the production of mesenchymal stem cells (MSCs) derived from mammalian muscular tissue
and the veterinary use of such stem cells in treating injured tissue.
BACKGROUND OF THE INVENTION
The use of stem cells in veterinary ne such as equine medicine opens the way to a wide
range of therapeutic opportunities by promoting an optimal regeneration of the injured tissue.
Indeed, tendinitis and osteoarthritis are very frequent pathologies in equine ne and
unfortunately have a poor sis. In fact, musculoskeletal injuries are the most common
source of injuries for ing . Although it is well known that (almost) adult s
have some tissue-specific progenitor cells, these are often not ient for an efficient repair.
Thus, ive regenerative medicine requires an exogenous input of cells in greater numbers
than those that are present normally within the tissue. These cells should both be able to
repair the lesion as well as to coordinate the healing process.
In current equine veterinary practice, the most commonly used stem cells are adult bone
marrow-derived and adipose tissue-derived hymal stem cells (MSCs), as well as
Wharton’s jelly MSCs (Schnabel et al., 2013, lacono et al., 2012). Bone marrow aspirate is
typically harvested from the sternum (marrow spaces 3-5) or ilium (Adams et al., 2012) and
adipose tissue is generally harvested from the tail head region (Gutierrez-Nibeyro, 2011).
Wharton’s jelly is isolated from umblical cord o et al., 2012). These sampling methods
are quite invasive, often not appreciated by owners of competing horses and can provoke
some infections.
A second shortcoming for veterinary research is the lack in cially available specific
antibodies. For this, human antibodies need to be used, and their cross reactivity in animals
such as horses needs to tested. As an example, only 4% of human antibodies react with
lent equine proteins. Valid phenotyping further necessitates proper use of
control isotypes to exclude non-specific antibody reactions and positive control cells to confirm
cross reactivity in e.g. horses. There are hence no standard specifications or markers to
ensure the quality of the animal or equine stem cells commercially available. Nevertheless,
some research groups have tried to effectively characterize mesenchymal stem cells (MSCs)
from various animal origins such as: bone marrow, e tissue, umbilical cord, umbilical
cord blood, Wharton’s jelly, peripheral blood and very recently periosteal tissue and muscle
(Radtke et al., 2013). Radtke and co-workers in this respect reported on a process for the
generation of equine muscle-derived mesenchymal stem cells , wherein large
muscular es (6g weight) are collected from horse cadavers. This method is hence highly
invasive and not useful for living and competing . Secondly, the stem cells ed are
isolated from the biopsies by means of enzyme digestion techniques, which limit the
possibilities. Third, the cells ed by the process of Radtke and co-workers are ve for
CD90 and CD44, but negative for CD45, CD34, CD146 and CD105. This negativity for CD105
was ed as being common in equine mesenchymal stem cells (MSCs) by Radtke et al.,
2013.
From the above, it is clear that new methods are needed for producing mesenchymal stem
cells (MSCs) from mammalians such as horses that involve a minimal invasive effort.
SUMMARY OF THE INVENTION
In y, stem cells used in regenerative medicine should be present in high quantity, able
to be collected and harvested by a minimally invasive procedure, capable of differentiating
along multiple cell lineage pathways in a reproducible manner, safely and effectively
transplanted either autologously, allogeneicly or xenogenously. Actually, these criteria are not
met in current veterinary regenerative ne.
The present invention therefore provides a new process for the generation of mammalian-
derived pluripotent mesenchymal stem cells (MSCs) from a micro-biopsy. A non-invasive
muscular micro-biopsy (10-20 mg) is collected on a living animal, for example from muscular
tissue from a horse, cultivated and used as explant to initiate the culture. Cells that came out
of the explant were centrifuged on a (discontinuous) density nt to select the part of the
cultured cell population with the greatest percentages of pluripotent cells. lmmunophenotyping
and eage differentiation unexpectedly indicated that the cellular populations selected by
density gradient fugation were found to be mesenchymal stem cells (MSCs), able to
differentiate into adipocytes, osteocytes and chondrocytes when cultured in the te
differentiation .
The mesenchymal stem cells (MSCs) of the present invention are positive for CD44, CD90
and CD105 and negative for CD45, MHCII and CD29. This is in contrast with the stem cells
obtained by Radtke et al., 2013, which were reported to be CD105 negative. Taking into
account the ISCT recommendations for stem cells (Dominici et al., 2006), the MSC
populations obtained herein can effectively be classified as pluripotent stem cells since they
are highly positive for CD90, CD105 and CD44, negative for CD45, MHCII and unexpectedly
for CD29.
The MSCs of the t invention are furthermore positive for miR-128, miR-133B, and miR-
802, slightly positive for miR—218 and ve for miR-656. This is in contrast with other
MSCs in the art, such as Wharton’s jelly MSCs or bone marrow MSCs. Wharton’sjelly MSCs
are negative for 8, miR—133B, miR-218 and miR-802 and positive for miR-656. Bone
marrow MSCs are positive for miR-218 and miR-802 and ve for miR-128, miR—13BB and
miR—656 (cf. Example section). Hence distinct differences exist in the properties of the MSCs
of the present invention and MSCs disclosed in the art.
Moreover these cells support a plurality of freeze-thawing cycles without loosing their
pluripotency.
The present invention hence offers a more effective and promising alternative to the methods
already described in the ture and, for the first time, provides the possibility of being
d out on living animals such as horses due to its minimally invasive ter.
In addition, cell culture is initiated with a more simple method than the enzyme ion
technique previously used (Radtke et al., 2013). For this, the ar microbiopsies are used
as explants and progenitor cells appear spontaneously in due time. By doing so, the number of
manipulations is reduced, avoiding potential sources of contamination. No external growth
factors need to be added, since the growth factors that are naturally ed by the muscle
microbiopsy (the explant) are ient.
Muscle-derived cells are a mixture of subpopulations form different lineages and different
pmental stages. On the basis of their density, related to their expression of specific
molecular markers, and thanks to a (discontinuous) density gradient, the method of the
invention is able to select three ntially pure subpopulations of pluripotent mesenchymal
stem cells out of the muscular explants.
All three subpopulations comprise >90% of cells that are CD44 positive. For CD90, the rate of
expression is 36% for 25-35% fraction, 48% for <15% fraction and 73% for 15-25% fraction.
For CD105, the rate of expression varies between 85 and 95% in the three populations. The
three populations also show different CFU-F and proliferative ties (cf. Examples
section).
In addition, it was shown that said mesenchymal stem cells (MSCs) can form fibroblasts-like
colonies in culture. In addition, unlike what is normally observed with other mesenchymal stem
cell sources, said cells can also differentiate into adipocytes, chondrocytes and osteocytes and
support a plurality of freeze-thawing cycles without lost of their pluripotency.
2014/077415
In an t to provide a less-invasive process for the generation of animal -derived
mesenchymal stem cells , the inventors found that combining muscular microbiopsy,
culturing of the explant and further enriching cells that emerged from the explant by
(discontinuous) density gradient centrifugation unexpectedly generates MSCs cells. It was
y unexpected that newly ted cells coming from the t spontanously during
culturing and further enriched by gradient centrifugation were mesenchymal stem cells
(MSCs).
The process of the invention allows the generation of a large quantity of mesenchymal stem
cells (MSCs) from a very small biopsy (microbiopsy), without an enzyme digestion step. Such
an anzyme digesion step would in any case be impossible to apply to a microbiopsy as
confirmed in ey, R.l. et al., 2005 (Culture of animal cells: A manual of basic technique.
5th Edition, Wiley, New York) disclosing that the ed amount of tissue for the cultivation
after an enzymatic digestion is about 1-5 g.
The MSCs obtained by the method according to the present invention s CD105, which
is a component of the TGF beta1 complex, having different important biological functions such
as angiogenesis and growth induction at the joint/articular level. For a comprehensive review
of TGF beta signaling in cartilage, please see Finnson KW et al., 2012 (Front Biosci (Schol
Ed). Jan 1;4:251-68).TGF beta1 stimulates chondrocyte division as well as cartilage matrix
synthesis. It is moreover found in platelets tives, like platelet-rich plasma, i.e. blood
plasma that has been enriched with platelets (PRP) (Lubkowska A et al., 2012, J Biol Regul
Homeost Agents. Apr-Jun;26(2 Suppl 1):3S—22S). As a concentrated source of autologous
platelets, PRP contains (and es through degranulation) several different growth factors
and other cytokines that stimulate healing of bone and soft tissue. Furthermore TGF beta1
decreases the release of PGE2 by osteoarthritic synovial fibroblasts and hence decreases
PGE2 stimulated matrix degradation in osteoarthritis (Fernandes J.C. et al., 2002,
Biorheology, 39, 237-46). The CD105 expression on the MSCs of the invention hence seems
to give excellent tissue regeneration characteristics to the obtained stem cells.
The invention hence provides the following aspects:
Aspect 1. A method for preparing mammalian mesenchymal stem cells (MSCs) sing the
steps of:
a) collecting a microbiopsy from said mammal,
b) after collection, placing said microbiopsy in suitable e medium,
c) collecting cells emerging from said microbiopsy during culturing,
d) growing the cells obtained in step c) to near confluency,
e) dissociating the cells from step d),
f) Separating mesenchymal stem cells (MSCs) from the other cells by y gradient
onation, thereby obtaining mesenchymal stem cells (MSCs). Said cells can optionally be
further purified by one or more lturing or passaging steps.
Aspect 2. The method according to aspect 1, wherein said microbiopsy is obtained from
skeletal muscle tissue, such as from muscles from the neck, shoulder, chest, back, tail, limbs,
hindlimb, forelimb, hindquarters, hindleg etc. preferably from triceps brachii muscle tissue,
more preferably taken from the long head of the triceps brachii.
Aspect 3. The method according to aspect 2, wherein said microbiopsy is collected at a depth
of about 5cm in the long head of the long head of the triceps brachii.
Aspect 4. The method according to any one of aspects 1 to 3, wherein said microbiopsy
contains about 15 to about 20 mg of tissue.
Aspect 5. The method according to any one of s 1 to 4, wherein said culture medium
comprises DMEM/F12 with about 20% fetal bovine serum, about 5m| penicillin (1000U/ml)—
streptomycin (10000pg/ml), about 2.5ml ericin B /ml) and about 5m| HEPES.
Aspect 6. The method according to any one of aspects 1 to 5, wherein in step d) the cells from
the density fraction below 35% is obtained.
Aspect 7. The method according to aspect 6, n in step d) the cells from density fractions
<15%, 15-25%, and/or 25-35% are obtained.
Aspect 8. The method ing to any one of aspects 1 to 7, wherein said mammal is
selected from the group comprising: ic and farm s, 200 animals, sport animals,
pet animals, companion animals and experimental animals, such as, for example, mice, rats,
hamsters, rabbits, dogs, cats, guinea pigs, cattle, cows, sheep, horses, pigs and primates,
e.g., monkeys and apes.
Aspect 9. A mesenchymal stem cell population obtained by the method according to any one
of aspects 1 to 8.
Aspect 10. A mesenchymal stem cell population, or the mesenchymal stem cell tion
according to aspect 9, characterized in that said cells express CD105, preferably wherein said
cells express CD105 in combination with CD44 and/or CD90.
Aspect 11. The mesenchymal stem cell population according to aspect 9 or 10, characterized
in that said cells do not express the following markers: CD45, MHC II and CD29.
Aspect 12. The mesenchymal stem cell population according to any one of aspects 9 to 11,
characterized in that said cells express at least one microRNA selected from the group
comprising: miR—128 and miR-133B.
Aspect 13. The mesenchymal stem cell population according to any one of aspects 9 to 12,
characterized in that said cells do not express the following microRNA: miR-656.
Aspect 14. A pharmaceutical or veterinary composition comprising the mesenchymal stem
cells obtained according to the method of any one of aspects 1 to 8, or sing a
mesenchymal stem cell population according to any one of aspects 9 to 13.
Aspect 15. The mesenchymal stem cell population according to any one of aspects 9 to 13, or
the pharmaceutical or nary ition of aspect 14, for use as a medicament or as a
pharmaceutical or veterinary agent.
Aspect 16. The mesenchymal stem cell population ing to any one of aspects 9 to 13, or
the ceutical or veterinary composition of aspect 14, for use in treating one or more of
the following disorders: desmitis, osteochondrosis, arthritis, osteoporosis, tendonitis, laminitis,
inflammation of the tendons and ligaments, fracture, and failure to heal in a mammalian
Aspect 17. The mesenchymal stem cell population for use according to aspects 15 or 16,
wherein autologous, allogeneic, or xenogenic mesenchymal stem cells (MSCs) are used.
Aspect 18. The method according to any one of aspects 1 to 8, additionally comprising the
step of differentiating the cells into ytes, osteocytes, chondrocytes, myogenic cells,
hematopoetic cells, endothelial cells, neural cells, cardiac cells, or hepatocytes by culturing the
MSCs in an adequate adipogenic, osteogenic, chondrogenic, myogenic, hematopoetic,
endothelial, neuronal, cardial, or cytic differentiation medium respectively. Preferably,
the method ing to any one of aspects 1 to 8 comprises the step of differentiating the
cells into adipocytes, osteocytes or chondrocytes, by culturing the MSCs in an adequate
adipogenic, osteogenic, or chondrogenic differentiation medium respectively.
Aspect 19. Differentiated adipocytes, osteocytes or chondrocytes, myogenic cells,
hematopoetic cells, endothelial cells, neural cells, cardiac cells, or hepatocytes, ed by
the method according to aspect 18.
Aspect 20. A ceutical or nary composition comprising the differentiated
adipocytes, ytes or chondrocytes according to aspect 19.
Aspect 21. The differentiated adipocytes, osteocytes or chondrocytes according to aspect 19,
or the pharmaceutical or veterinary composition according to aspect 20, for use in treating one
or more of the ing disorders: desmitis, osteochondrosis, arthritis, osteoporosis,
tendonitis, laminitis, inflammation of the tendons and ligaments, fracture, and e to heal in
a mammalian subject.
Aspect 22. A method of treating one or more of the following disorders: desmitis,
osteochondrosis, arthritis, orosis, tendonitis, laminitis, inflammation of the tendons and
nts, fracture, and failure to heal in a ian subject sing the step of
administering to said subject a therapeutically effective amount of MSCs obtained through the
method of any of aspects 1 to 8, or of the veterinary or pharmaceutical composition according
to aspect 14, thereby treating said one or more er(s) in said mammalian subject.
Aspect 23. A method of treating one or more of the following ers: desmitis,
osteochondrosis, arthritis, osteoporosis, tendonitis, laminitis, inflammation of the tendons and
ligaments, fracture, and failure to heal in a mammalian subject comprising the step of
administering a therapeutically effective amount of differentiated ytes, osteocytes or
chondrocytes, myogenic cells, hematopoetic cells, endothelial cells, neural cells, c cells,
or hepatocytes obtained h the method of aspect 18, or of the veterinary or
pharmaceutical ition according to aspect 20, thereby treating said one or more
disorder(s) in said mammalian subject.
Aspect 24. The methods according to aspect 22 or 23, wherein said administered cells are
autologous, allogeneic, or xenogenic.
BRIEF DESCRIPTION OF THE FIGURES
The present ion is illustrated by the following figures which are to be considered for
rative purposes only and in no way limit the invention to the ments disclosed
therein:
Figure 1: Representative microscopic photography of morphological aspect of fibroblasts-like
colony forming units obtained with cells from each Percoll fraction seeded at low density
(500000 cells/flask) and grown for 10 days (May-Grunwald Giemsa staining; A: 100x; B: 400x
magnification).
Figure 2: Control FACS images showing the cross reactivity of the chosen antibodies on
mononucleated cells from equine bone marrow.
Figure 3: Representative flux cytometry histograms of cells from 15-25% Percoll fraction
(Horse 2). These cells are highly positive for CD105, CD90 and CD44 but negative for CD45.
Figure 4: Representative microscopic photographs of the adipocytic differentiation obtained
for horse 2 after 7 days in differentiation medium (Oil Red 0 solution staining, 400x
magnification). <15%, , 25-35% represents the cells from the 3 Percoll ons,
Control represents the cells for which no differentiation was d.
Figure 5: Representative photographs of thin cuts staining with Alcian Blue, of the
chondrosphere obtained after 3 weeks of culture in the chondrogenic differentiation medium
(A) or of the control pellet (B; cells not cultured with chondrogenic entiation medium).
Figure 6: Representative microscopic photographs of the osteogenic differentiation obtained
for horse 2 after 7 days in differentiation medium (Alizarin Red on ng, 400x
magnification). <15%, 15-25%, 25-35% represented the cells from the 3 Percoll fractions,
Control represented the cells for which no entiation was induced.
Figure 7: Represents differential level of expression (number of copies detected) of 5 miRNAs
in 3 s of horse hymal stem cells (MSCs), i.e. Wharton’s jelly MSCs, bone
marrow MSCs and muscle-derived MSCs according to the present invention.
DETAILED DESCRIPTION OF THE INVENTION
As used , the singular forms :5 n n :1
a, an, and “the” include both singular and plural
referents unless the context clearly dictates othenNise. By way of example, “a cell” refers to
one or more than one cell.
The terms "comprising II n
, comprises” and “comprised of’ as used herein are synonymous with
"including", “includes” or "containing , contains”, and are inclusive or open-ended and do not
exclude additional, non-recited members, elements or method steps.
The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed
within the tive ranges, as well as the recited endpoints.
The term "about" as used herein when referring to a measurable value such as a parameter,
an amount, a temporal duration, and the like, is meant to encompass variations of +/-10% or
less, preferably +/-5% or less, more preferably +/-1% or less, and still more preferably +/-0.1%
or less of and from the specified value, insofar such variations are appropriate to perform in
the disclosed invention. It is to be understood that the value to which the modifier "about"
refers is itself also specifically, and preferably, disclosed.
All references cited in the present specification are hereby incorporated by reference in their
entirety. In particular, the ngs of all references herein specifically referred to are
incorporated by reference.
Unless ise defined, all terms used in disclosing the invention, including cal and
scientific terms, have the meaning as commonly understood by one of ordinary skill in the art
to which this invention s. By means of r guidance, term definitions are included to
better appreciate the teaching of the present invention.
For general methods relating to the invention, reference is made to well-known textbooks,
including, e.g., “Molecular Cloning: A Laboratory Manual, 2nd Ed.” (Sambrook et al., 1989),
Animal Cell Culture (R. l. Freshney, ed., 1987), the series Methods in Enzymology (Academic
Press), Gene er Vectors for Mammalian Cells (J. M. Miller & M. P. Calos, eds., 1987);
“Current ols in Molecular Biology and Short ols in Molecular Biology, 3rd Ed.” (F.
M. Ausubel et al., eds., 1987 & 1995); Recombinant DNA Methodology II (R. Wu ed.,
Academic Press 1995), incorporated by reference herein.
For r ation of general techniques useful in the practice of this invention, the
practitioner can refer to standard textbooks and reviews in cell biology, tissue culture, and
embryology. Included are “Teratocarcinomas and embryonic stem cells: A practical approach”
(E. J. Robertson, ed., lRL Press Ltd. 1987); “Guide to ques in Mouse Development” (P.
M. man et al. eds., ic Press 1993); onic Stem Cell Differentiation in
Vitro” (M. V. Wiles, Meth. Enzymol. 225:900, 1993); “Properties and uses of Embryonic Stem
Cells: Prospects for Application to Human Biology and Gene Therapy” (P. D. Rathjen et al.,
al.,1993). Differentiation of stem cells is reviewed, e.g., in Robertson. 1997. Meth Cell Biol 75:
173; and Pedersen. 1998. Reprod Fertil Dev 10: 31, and Usas et al., 2011, incorporated by
reference .
General techniques in cell culture and media collection are outlined in Large Scale Mammalian
Cell Culture (Hu et al. 1997. Curr Opin Biotechnol 8: 148); Serum-free Media (K. Kitano. 1991.
Biotechnology 17: 73); Large Scale Mammalian Cell Culture (Curr Opin hnol 2: 375,
1991 ), incorporated by reference herein.
The term “stem cell” refers generally to an unspecialised or relatively less specialised and
proliferation-competent cell, which is capable of self-renewal, i.e., can proliferate without
differentiation, and which or the progeny of which can give rise to at least one relatively more
specialised cell type. The term encompasses stem cells capable of substantially unlimited self-
renewal, i.e., wherein the progeny of a stem cell or at least part thereof substantially retains
the unspecialised or relatively less specialised phenotype, the differentiation ial, and the
proliferation capacity of the mother stem cell, as well as stem cells which display limited self-
renewal, i.e., wherein the capacity of the progeny or part thereof for further eration and/or
differentiation is demonstrably reduced compared to the mother cell. By means of example
and not limitation, a stem cell may give rise to descendants that can differentiate along one or
more es to produce increasingly relatively more specialised cells, wherein such
descendants and/or increasingly relatively more specialised cells may themselves be stem
cells as defined herein, or even to produce terminally differentiated cells, i.e., fully specialised
cells, which may be post-mitotic.
The term “mesenchymal stem cell” or “MSC” as used herein refers to a mammalian adult,
mesoderm-derived stem cell that is capable of generating cells of mesenchymal lineages,
typically cells of two, preferably of three or more mesenchymal es, e.g., osteocytic
(bone), chondrocytic (cartilage), ic (muscle), tendonocytic (tendon), fibroblastic
ctive tissue), adipocytic (fat) and stromogenic (marrow stroma) lineage. Commonly, but
without limitation, a cell may be considered MSC if it is capable of forming cells of each of the
adipocytic, chondrocytic and osteocytic lineages, using standard, cepted differentiation
conditions and cellular phenotype evaluation methods, e.g., as described in Pittenger et al.
1999 (Science 284: 143-7) or Barberi et al.,2005 (PLoS Med 2: e161), and Usas et al., 2011.
The term MSC also encompasses the progeny of MSC, e.g., progeny obtained by in vitro or ex
vivo propagation of MSC obtained from a biological sample of a subject.
The term “isolating” with reference to a particular component denotes separating that
component from at least one other component of a composition from which the former
component is thereby “isolated”. The term ted” used in relation to any cell, group of cells
or a cell population also implies that such cell, group of cells or cell population does not form
part of an animal body.
The ISCT determined precisely the ies cells must s to be defined as
mesenchymal stem cells (MSCs) as follows: the cells must be plastic-adherent, positive for the
markers CD73, CD90 and CD105, negative for the markers CD14 (or CD1 1 b), CD34, CD45,
CD79a (or CD19) and MHC-ll, and must exhibit the y to differentiate into cells of
mesodermal origin such as osteoblasts, chondroblasts and adipocytes (Dominici et al., 2006).
The use of other MSC markers such as CD29 or CD44 was also ed (Pittenger et al.,
1999). The ISCT criteria were extended to the invention herein. The ian MSC cells of
the present invention hence are defined in that they express or co-express (i.e., are positive
for) at least the mesenchymal marker CD105, and ably also one or more of the following
markers: CD44 and CD90. The mammalian MSC cells of the present invention are also
defined in that they s or co-express (i.e., are positive for) one or more of the following
microRNAs: miR-128, miR—133B, miR—218 or 2. The mammalian MSC cells of the
present ion are also defined in that they do not eXpress miR-656.
Throughout this specification "co-express" intends to cover the g "comprising co-
expression of" such that the cells can express other markers or microRNAs in addition to the
particular recited markers or microRNAs characterising the cells.
The terms NA, miRNA, miR or R are used herein interchangeably, and refer to
19-25 nucleotides mature non-coding RNAs or precursors thereof, or fragments thereof,
derived from endogenous genes of living organisms such as s. Mature NAs are
processed from longer hairpin-like precursors termed pre-microRNAs (pre-miRs) having a
length of approximately 75 nucleotides.
Where a cell is said to be positive for a particular marker or microRNA, this means that a
skilled person will conclude the presence or evidence of a distinct signal, e.g., antibody-
able or ion by e transcription polymerase chain reaction, for that marker or
microRNA when carrying out the appropriate measurement, compared to suitable controls.
Where the method allows for tative assessment of the marker or microRNA, positive
cells generate a signal that is significantly different from and higher or stronger than the
control, e.g., but without limitation, at least 1.5-fold higher than such signal generated by
control cells, e.g., at least 2-fold, at least 4-fold, at least 10-fold, at least 20-fold, at least 30-
fold, at least 40-fold, at least 50-fold higher or even higher.
The sion of cell-specific markers can be detected using any suitable immunological
technique known in the art, such as immuno-cytochemistry or affinity adsorption, Western blot
analysis, FACS, ELISA, etc., or by any suitable biochemical assay of enzyme activity, or by
any suitable technique of measuring the quantity of the marker mRNA, e.g., rn blot,
semi-quantitative or quantitative , etc.
The expression of microRNAs may be determined, for example, with an assay for global gene
expression (e.g. using a microarray assay for NAs expression ing analysis, a
ready-to-use microRNA qPCR plate or RNA sequencing) or by specific detection assays, for
example, but not limited to, quantitative PCR, quantitative reverse-transcription (real-time)
PCR (qRT—PCR), locked nucleic acid (LNA) real-time PCR, or northern blotting. In particular,
the measurement of the expression of a microRNA may be carried h an oligonucleotide
probe specific for the detection of said microRNA. Said oligonucleotide probe may bind directly
and specifically to the microRNA, or may specifically reverse transcribe said microRNA.
Alternatively, said oligonucleotide probe may bind a cDNA obtained from said microRNA. Said
oligonucleotide probe may also amplify a cDNA obtained form said microRNA.
Nucleic and amino acid sequence data for marker proteins listed in this disclosure are
generally known and can be obtained from public databases such as, among others, from the
NIH “Protein s on the Web” database (http://mpr.nci.nih.gov/prow/), the NIH “Entrez
Gene” database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) or the Uniprot/Swissprot
database (http://www.expasy.org/). Suitable detection reagents and methods for said markers
can be designed either on the basis of such sequence information or, more commonly, are
available commercially (e.g., labelled monoclonal antibody ts).
The term ” encompasses the antigen known as CD105, or its ms such as
endoglin. CD105 is a membrane glycoprotein located on cell surfaces and is a known
hymal stem cell marker. As an e, the partial amino acid sequence of the equine
CD105 antigen can be found in the Genbank database under accession number
AGW16345.1.
The term “CD90” encompasses the antigen CD90, or its synonyms such as Thy-1 membrane
glycoprotein. As an example, the amino acid sequence of the equine CD90 antigen can be
found in the Genbank database under accession number ACG61223.1.
The term “CD44” encompasses the antigen generally known as CD44, or its synonyms such
as Extracellular matrix receptor |||, GP90 lymphocyte homing/adhesion receptor, HUTCH-l,
Hermes antigen, onate receptor, or Phagocytic glycoprotein 1. As an example, the
amino acid sequence of the equine CD44 antigen can be found in the Genbank database
under accession number CAA47331.1.
Exemplary commercially available antibody reagents for detection of said MSC markers
e inter alia monoclonal antibodies anti-CD105-RPE (ABD Serotec), anti-CD44-APC (BD
Pharmigen), and anti-CD90 (VMDR). Alternative antibodies that are specifically binding to
CD105, CD44, or CD90 can be identified by the person skilled in the art.
In an embodiment, the MSCs express at least one mesenchymal marker chosen from: CD105,
CD90 and CD44. Preferably, the MSCs express at least mesenchymal marker CD105. The
invention contemplates MSC cells, which co-express CD105 and CD90, cells which co-
s CD90 and CD44, as well as cells which co-express CD105 and CD44. Also covered
are cells, in particular MSC cells, which ress CD105, CD90, and CD44. As shown in the
examples, MSC cells of the above marker profile may also co-express other markers.
In another embodiment, the MSCs express at least one microRNA ed from the group
comprising: miR-128 and miR—133B. The invention contemplates MSCs which express at least
miR—128 or MSCs which express at least 38. Also covered are MSCs which co-express
8 and miR-133B. In a further embodiment, the MSCs do not express the following
microRNA: miR-656.
MicroRNAs listed in this disclosure are generally known and can be ed from public
databases such as, among others, the miRBase database //www.mirbase.org).
The term “miR-128” encompasses the microRNA known as miR-128 or its precursor. As an
example, the nucleotide sequence of the equine miR—128 can be found in the miRBase
database under accession number Ml0012821.
The term “miR-133B” encompasses the microRNA known as miR—133B or its precursor. As an
example, the nucleotide sequence of the equine 3B can be found in the miRBase
database under accession number 844.
The term “miR-656” encompasses the microRNA known as 6 or its precursor. As an
example, the nucleotide sequence of the equine miR—656 can be found in the miRBase
database under accession number Ml0012915.
The skilled person is well aware that microRNAs may be referred to by different names, or
synonyms.
The MSC cells may further display certain morphological features, such as any one or more of
adherence to tissue culture plastic; growth in monolayers; and clear ovoid, stellate or
spindle shape with round to oval nuclei having prominent nucleoli.
The term "cell population" generally refers to a grouping of cells. A cell population may consist
of or may se at least a fraction of cells of a common type, or having characteristics in
common. Such teristics may include, without limitation, morphological characteristics,
potential for differentiation (e.g., otent, multipotent, unipotent, etc.; e.g., if multipotent or
unipotent, ability to differentiate towards specific cell , or the presence and/or level of
one, two, three or more cell-associated markers, e.g., surface antigens. Such characteristics
may thus define a cell population or a fraction thereof. Preferably, such a cell population is
mesenchymal stem cell population, more preferably a substantially homogenous population of
hymal stem cells.
The term “substantially homogeneous” or “substantially pure” population of hymal stem
cells denotes a cell population comprising a fraction of MSCs as defined above, wherein said
fraction in said cell population is at least 50%, e.g., at least 55%, preferably at least 60%, e.g.,
at least 65%, more preferably at least 70%, e.g., at least 75%, even more preferably at least
80%, e.g., at least 85%, most ably at least 90%, e.g., at least 91%, at least 92%, at least
93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or
even close to or equal to 100%.
The expression “density gradient centrifugation” encompasses all types of cell-separation
techniques or products encompassing the density-based separation of cells. Non-limiting
examples can be density gradient centrifugation in a gradient of sucrose r, or dal
silica. Non-limiting examples of commercially available gradients are: l (colloidal silica
coated with polyvinylpyrrolidone or silane), ficoll (high molecular weight sucrose-polymers),
-Paque (Ficoll plus sodium diatrizoate and edetate calcium disodium), t density
solution (BDS, comprising colloidal silica), lymphoprep (sodium diatrizoate and
polysaccharide), etc. It is clear that the skilled artisan will be able to select suitable gradients to
separate the stem cells obtained wit the method according to the present invention. Using the
methods of the present invention, the mesenchymal stem cells (MSCs) are typically found in
the <15%, 15-25%, or 25-35% Percoll density interfaces, after centrifugation at 1250 x g
(25°C, 20min). Mesenchymal stem cells co-expressing the desired marker proteins can then
be selected, enriched or isolated from the general population of isolated and optionally
ed cells by s known per se, such as, for example, using fluorescence activated
cell-sorting (FACS), magnetic-activated cell sorting (MACS), affinity-based technologies inter
alia affinity tography, or the preplate technique and combinations thereof. Exemplary
methods are reported in Wu et al., 2010 (cf. Cell Tissue Research, Jun;340(3):549-67).
Live cells having a desired expression profile are allowed to bind with reagents (most
commonly immunological reagents such as, e.g., onal antibodies) specific for the
respective markers, wherein said reagents are in turn modified (e.g., by a fluorophore, or by
immobilisation on ic les or another type of nary phase), such as to tate
for selection or capture of cells bound by said reagents from cells not so bound. For general
guidance on these s, refer inter alia to Flow Cytometry and Cell Sorting, 2nd ed., by
s Radbruch (ed.), er 1999 (ISBN 3540656308); In Living Color: Protocols in Flow
Cytometry and Cell Sorting, 1st ed., by RA Diamond and S Demaggio (eds.), Springer 2000
(ISBN 3540651497); Flow Cytometry Protocols (Methods in Molecular Biology), 2nd ed., by TS
Hawley and RG Hawley (eds.), Humana Press 2004 (ISBN 1588292355); Affinity Separations:
A Practical Approach, P Matejtschuk (ed.), Oxford University Press, 1997 (ISBN 0199635501);
and Dainiak et al. 2007. Adv Biochem Eng Biotechnol 106: 1-18.
The expression “suitable culture medium” encompasses all cell-culturing media that support
the survival and/or growth of the cells mesenchymal stem cells (MSCs) or mesenchymal stem
cell populations. Non-limiting examples are: DF20, DMEM-Ham’s F12, DMEM, Alpha-MEM
etc., typically supplemented with at least antibiotics and fetal bovine serum (FBS), and
optionally with antifungal agents and buffers.
As an example only, the following e medium has been used in the examples: DF20
medium comprising: DMEM/F12 with about 20% fetal bovine serum, about 5m| llin
(1000U/ml)—streptomycin (10000pg/ml), about 2.5ml amphotericin B (250pg/ml) and about 5ml
HEPES.
For differentiation into e.g. adipocytes, osteocytes and chondrocytes, the MSCs or
mesenchymal stem cell populations of the invention where cultured in an adequate
rentiation medium”. Said differentiation medium can for example be: for enic
differentiation: NH AdipoDiff Medium nyi Biotec); for chondrogenic differentiation:
chondrocyte differentiation medium (NH ChondroDiff Medium; Miltenyi ); for osteogenic
differentiation: osteogenic medium (NH OsteoDiff Medium; Miltenyi Biotec). The media listed
herein are merely shown as exemplary media, but the skilled person will be able to use any
other commercial or specifically developed differentiation medium. Other examples of suitable
differentiation media for other cells such as myogenic cells, hematopoetic cells, endothelial
cells, neural cells, cardiac cells, or hepatocytes can be done by culturing the MSCs in an
adequate myogenic, poetic, endothelial, neuronal, cardial, or hepatocytic differentiation
medium respectively, examples of which can e.g. be found in Usas et al., 2011.
Appropriate ways of “detaching”, “dispersing”, “dissociating” or “disassociating” cells are
generally known in the art and may be used in the present ion. These involve, e.g.,
treatment with proteolytic s, chelation of nt ions, mechanical disintegration, or
combinations of any of the above. Preferably, said cell dissociation may involve enzymatic
digestion, favourably using trypsin (e.g., as described above), optionally in combination with
ion of bivalent ions, favourably using EDTA (e.g., as described above), and/or
mechanical dissociation of the so-treated cells. The latter may e, e.g., repeated passing
of the cells through a small bore pipette (e.g., a 1000u| micropipette tip) and/or ing out a
stream of a suspension containing the cells against a solid surface (e.g., against the wall of the
culture vessel). In this way a cell suspension sing MSCs of the invention can be
obtained.
The term biopsy” encompasses all minimally invasive and preferable -free
subcutaneous collection methods of a tissue sample. The sample size of a microbiopsy is, as
the term defines, very small and typically comprises about 15 to about 20 mg of tissue. Any
possible technique or device suitable for collecting iopsies can be used. Non-limiting
examples are iopsy s, conchotomes or spring-loaded micro-biopsy systems
known in the art. As an example only, a 14-gauge microbiopsy needle and a microbiopsy pistol
can be used.
The source of the microbiopsy used in the method of the present invention for isolating
mesenchymal stem cells (MSCs) is preferably skeletal muscle-related tissue from mammals.
Examples of skeletal muscle-related s are muscles of the neck, shoulder, chest, back,
tail, limbs, hindlim, forelimb, hindquarters, hindleg etc. The exemplary used muscle tissue in
the examples is the triceps brachii muscle from horse, more preferably, taken from the long
head of the triceps brachii, most preferably taken at a depth of about 5cm in the long head of
the long head of the triceps brachii. Harvesting muscle tissue is preferable to e.g. bone
marrow or periosteal tissue, because of the quantity but also of the easiness of access of
muscular tissue and the low morbidity at this donor site. Embryonic tissue is explicitly
excluded as a source of microbiopsy. A study performed by Votion et al., 2010 trated
that microbiopsy performed by veterinarians in al practice is feasible. Furthermore, the
absence of adverse effects permits eration of this method of sample collection for use
on high-performance horses, even during competitions n et al., 2010) and is y
used to successfully initiate, by t method, a primary culture of equine skeletal myoblasts
(Ceusters et al., 2012).
The expression “mammal” or “mammalian” refers to all mammals, including, but not limited to,
domestic and farm animals, 200 animals, sport animals, pet animals, companion animals and
experimental animals, such as, for example, mice, rats, hamsters, rabbits, dogs, cats, guinea
pigs, , cows, sheep, horses, pigs and primates, e.g., monkeys and apes. Preferred
mammals are horses, dogs, or cats.
As explained , the mesenchymal stem cells obtained from said microbiopsies are cells
that neously emerge around the microbiopsy when cultured according to the method as
claimed. The term “emerging” encompasses the spontaneous occurrence of cells, i.e. without
the need of manipulation of the biopsy, or t the need of adding additional growth,
differentiation, or other factors or agents. The culturing step of the microbiopsy, also called
explant at this stage, unexpectedly and spontaneously generates mesenchymal stem cells that
can be further subcultured, purified and preserved by e.g. cryopreservation as defined herein.
Suitable media for said culturing of said microbiopsy are DF20, DMEM-Ham’s F12, DMEM,
Alpha-MEM etc. Said media are typically containing or are supplemented with at least
antibiotics and fetal bovine serum (FBS), and optionally with antifungal agents and buffers.
The present invention provides also methods of treatment by administering the differentiated
or non-differentiated MSCs or differentiated or non-differentiated mesenchymal stem cell
populations as defined herein particularly to be given to subjects in need thereof, which phrase
includes subjects that would benefit from treatment of a given condition, such as thro-
skeletal disorders. Such subjects may include, without limitation, those that have been
diagnosed with said condition, those prone to develop said condition and/or those in whom
said condition is to be prevented.
The term ct” encompasses all mammals, including, but not limited to, domestic and farm
animals, 200 animals, sport animals, pet s, companion s and experimental
animals, such as, for example, mice, rats, hamsters, rabbits, dogs, cats, guinea pigs, cattle,
cows, sheep, , pigs and primates, e.g., monkeys and apes. Preferred subjects are
horses, dogs, or cats.
The terms “treat” or “treatment” encompass both the therapeutic ent of an already
developed disorder, such as the y of an already developed myo-arthro-skeletal disorder,
as well as prophylactic or preventative measures, wherein the aim is to prevent or lessen the
chances of incidence of an undesired affliction, such as to t the chances of contraction
and progression of a thro-skeletal disorder such as but not limited to: desmitis,
osteochondrosis, arthritis, osteoporosis, tendonitis, inflammation of the tendons and ligaments,
2014/077415
fracture, and failure to heal. Beneficial or desired clinical results of such a ent may
include, without limitation, alleviation of one or more symptoms or one or more biological
markers, diminishment of extent of disease, stabilised (i.e., not worsening) state of disease,
delay or slowing of disease progression, amelioration or palliation of the disease state, and the
like. “Treatment” can also mean prolonging survival as compared to expected survival if not
ing treatment.
The term “prophylactically effective amount” refers to an amount of the veterinary or
pharmaceutical composition according to the invention that inhibits or delays in a subject the
onset of a disorder as being sought by a researcher or veterinarian. The term “therapeutically
effective amount” as used herein, refers to an amount of the veterinary or pharmaceutical
composition ing to the invention that elicits the biological or medicinal response in a
subject that is being sought by a researcher, or veterinarian, which may include inter alia
alleviation of the symptoms of the disease or disorder being treated. Methods are known in the
art for determining therapeutically and prophylactically ive doses.
The treatment may employ autologous (i.e., cells derived from the subject to be treated),
allogeneic (i.e., cells derived from subject(s) other than the subject to be treated, but ing
to the same species) or xenogenic (i.e., cells derived from subject(s) belonging to species
other than the subject to be treated) MSCs, differentiated MSCs or their tive cell
populations as defined .
The veterinary or pharmaceutical itions will typically comprise the hymal stem
cells, differentiated mesenchymal stem cells, or respective (differentiated) mesenchymal stem
cell tions of the invention as the active ingredient, and one or more pharmaceutically
acceptable carrier/excipient. As used herein, "carrier" or ient" includes any and all
solvents, diluents, buffers (such as, e.g., neutral buffered saline or phosphate ed saline),
solubilisers, colloids, dispersion media, vehicles, fillers, chelating agents (such as, e.g., EDTA
or glutathione), amino acids (such as, e.g., e), proteins, disintegrants, binders, ants,
wetting agents, emulsifiers, sweeteners, colorants, flavourings, aromatisers, thickeners,
agents for achieving a depot effect, coatings, antifungal agents, preservatives, stabilisers,
antioxidants, tonicity controlling agents, absorption delaying agents, and the like. The use of
such media and agents for veterinary or pharmaceutical active substances is well known in the
art. Such materials should be non-toxic and should not interfere with the activity of the cells.
For veterinary use, the cells could also be formulated in, or administered as, a feed
supplement.
The precise nature of the carrier or excipient or other material will depend on the route of
administration. For example, the ition may be in the form of a parenterally acceptable
aqueous solution. For general principles in medicinal formulation, the reader is referred to Cell
Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular lmmunotherapy, by G.
Morstyn & W. Sheridan eds., Cambridge University Press, 1996; and Hematopoietic Stem Cell
Therapy, E. D. Ball, J. Lister & P. Law, Churchill Livingstone, 2000.
Such nary or pharmaceutical compositions may contain further components ensuring the
viability of the (differentiated) mesenchymal stem cells or cell populations therein. For
example, the compositions may comprise a le buffer system (e.g., phosphate or
carbonate buffer system) to achieve desirable pH, more usually near neutral pH, and may
comprise sufficient salt to ensure isoosmotic conditions for the MSCs to prevent osmotic
stress. For example, suitable solution for these purposes may be phosphate-buffered saline
(PBS), sodium de solution, Ringer's ion or Lactated Ringer's Injection, as known in
the art. Further, the composition may comprise a carrier protein, e.g., albumin, which may
increase the viability of the MSCs.
The veterinary or pharmaceutical compositions may comprise further components useful in the
repair of bone wounds and defects. For example, such ents may include without
limitation bone morphogenetic proteins, bone matrix (e.g., bone matrix ed in vitro by
cells of the invention or by other methods), hydroxyapatite/tricalcium phosphate particles
(HA/TCP), gelatine, poly-lactic acid, poly-lactic g|yco|ic acid, hyaluronic acid, chitosan, poly-L-
|ysine, and collagen. For example, the osteoblastic cells may be combined with demineralised
bone matrix (DBM) or other matrices to make the composite osteogenic (bone forming in it
own right) as well as osteo-inductive. Similar methods using autologous bone marrow cells
with allogeneic DBM have d good results.
The veterinary or pharmaceutical composition can further include or be co-administered with a
complementary bioactive factor such as a bone morphogenic protein, such as BMP-2, BMP-7
or BMP-4, or any other growth factor. Other potential anying components e
inorganic sources of calcium or phosphate le for assisting bone regeneration (WO
00/07639). If desired, ce|| preparation can be administered on a carrier matrix or al to
provide improved tissue regeneration. For example, the material can be a granular ceramic, or
a biopolymer such as gelatine, en, osteonectin, fibrinogen, or osteocalcin. Porous
matrices can be synthesized ing to standard ques (e.g., Mikos et aI., erials
14: 323, .
The veterinary or pharmaceutical composition can further include or be co-administered with a
complementary disinfecting, aseptic, or microorganism destroying agent such as a
bactericidal, antibacterial, antibiotic, or antifungal and/or an anti-inflammatory agent in order to
avoid complications due to infection and or inflammation at the site of introduction or
administration of the MSCs.
In a further aspect, the invention relates to an arrangement comprising a surgical instrument
for stration of the MSC-comprising composition to a subject, such as for example
systemically, lly or at a site of a lesion, and further comprising the MSCs or cell
populations of the invention, or a veterinary or pharmaceutical composition comprising said
MSCs or cell populations, wherein the ement is adapted for administration of the
veterinary or pharmaceutical composition for example systemically, topically or at the site of
bone lesion. For e, a suitable surgical instrument may be capable of injecting a liquid
composition comprising MSCs or cell populations of the present invention, such as
systemically or at the site of bone lesion.
The MSCs or cell populations can be administered in a manner that s them to graft or
e to the intended tissue site and reconstitute or regenerate the onally deficient
area. Administration of the composition will depend on the myo-arthro-skeletal site being
repaired. For example, the MSCs or cell populations can be administrated either ly in the
s (such as for example in tendon or ligament), or in the synovial joints (such as for
example the tendinous or articular synovials).
For example, osteogenesis can be tated in concordance with a surgical procedure to
remodel tissue or insert a split, or a prosthetic device. In other circumstances, invasive surgery
will not be required, and the composition can be stered by ion, such as ultra-sound
guided injection, or using a guidable endoscope.
In another embodiment, the differentiated or undifferentiated MSCs or mesenchymal stem cell
populations of the ion may be transferred to and/or cultured on suitable substrates to
provide for implants. The substrate on which the cells can be applied and cultured can be a
metal, such as titanium, cobalt/chromium alloy or ess steel, a bioactive surface such as a
calcium phosphate, polymer es such as polyethylene, and the like. Although less
preferred, siliceous material such as glass ceramics, can also be used as a substrate. Most
preferred are metals, such as titanium, and calcium phosphates, even though calcium
phosphate is not an indispensable component of the substrate. The ate may be porous
or non-porous. The substrate may be biodegradable or bio-absorbable.
For example, MSCs of the invention that have proliferated, or that are being differentiated in
culture dishes, can be transferred onto three-dimensional solid ts in order to cause
them to multiply and/or continue the differentiation process by incubating the solid support in a
liquid nutrient medium of the invention, if necessary. Cells can be transferred onto a three-
dimensional solid support, e.g. by impregnating said support with a liquid suspension
containing said cells. The nated supports obtained in this way can be implanted in a
subject. Such impregnated supports can also be re-cultured by immersing them in a liquid
culture medium, prior to being finally implanted.
The three-dimensional solid support needs to be biocompatible so as to enable it to be
implanted in a subject. It can be of any suitable shape such as a cylinder, a sphere, a plate, or
a part of arbitrary shape. Of the materials suitable for the biocompatible three-dimensional
solid t, particular mention can be made of calcium carbonate, and in particular
aragonite, specifically in the form of coral skeleton, porous ceramics based on alumina, on
zirconia, on cium phosphate, and/or hydroxyapatite, imitation coral skeleton obtained by
hydrothermal exchange enabling calcium carbonate to be transformed into hydroxyapatite, or
else apatite-wollastonite glass ceramics, bioactive glass ceramics such as Bioglass(TM)
glasses.
The present invention is r illustrated by the following examples, which do not limit the
scope of the invention in any way.
EXAMPLES
Materials and Methods
1. The sampling method: muscular microbiopsy
Microbiopsy procedures were performed on standing, awake horses. Microbiopsy specimens
were ed from triceps brachii s (long head, at the intersection of a vertical line
extending from the tricipital crest and a line n the scapulo- and radio-humeral joints) of
each horse (n=3).
Microbiopsy specimens were collected with a 14-gauge iopsy needle and a microbiopsy
pistol. Briefly, the sampling site was shaved (one cm square) and aseptically prepared. Each
sample (approximately 15 to 20 mg of tissue) was collected at a depth of 5 cm in the long
head of the triceps brachii muscle, through a skin incision made with the tip of a scalpel blade
nr 11. e of the skin incision was not necessary and the whole microbiopsy procedure
was completed within 15 s. Immediately after collection, each sample was placed in 6ml
of culture medium composed of DMEM/F12 with 20% fetal bovine serum, 5ml penicillin
(1000U/ml)—streptomycin pg/ml), 2.5ml ericin B (250pg/ml) and 5ml HEPES
. Microbiopsy specimens were kept in growth medium at 4°C until use.
WO 91210 2014/077415
2. Initiation of the cell cultures by using microbiopsy specimens as explants
Culture preparation was performed by use of sterile equipment, under a streamline flow hood.
Microbiopsy specimens were washed twice in 5ml of DF20 preheated to 37°C. Each
iopsy specimen was carefully dissected g to keep as much as possible only
muscular tissue) in 10mM PBS solution (pH, 7.4) containing 137mM NaCl and 2.7mM KCI,
then cut in small pieces (size of the tip of the l blade). Then, each pieces was placed
individually into the 16 central wells of 24-mutliwell dish, 100p| of DF20 were added to each
well, and culture dishes were incubated at 37°C under controlled atmosphere (5% C02 and
21% 02). The outer wells were filled with PBS (1mI/well) to prevent drying out of well
containing explants. Wells containing explants were monitored each day and fed by simple
addition of new DF20 when ary (keeping the growth factors within the wells).
When a halo of cells was visible around the tissue (about 10 days), the muscle pieces were
individually transferred to another 24-mutliwell dish (16 central wells for muscle pieces and the
outer wells filled with PBS); the cells that had separated from the microbiopsy were grown to
80% confluence (about 20 days).
3. Trypsination of the cells and pluripotent stem cells isolation: Discontinuous Percoll
density gradient fugation
Nearly confluent cells obtained from explants were detached using tryspin-EDTA, centrifuged
(200 x g, 10 min, 37°C) and the pellet was resuspended in 1ml of HBSS. The ar
sion was then placed on a discontinuous Percoll density gradient prepared as follows:
Sodium Chloride solutions with 15%, 25% and 35% of Percoll were prepared. Then, 2ml of
each Percoll on was added to a 15-ml culture tube to form the discontinuous Percoll
density gradient above which 1ml of the cellular suspension was placed. The cell ons with
different densities appeared at the interfaces between each Percoll on after centrifugation
at 1250 x g (25°C, 20min). Each fraction (<15%, 15-25%, 25-35%) was individually collected,
washed once with HBSS (1mI/fraction) and centrifuged at 200 x g, 10 min at 37°C. The
supernatants were discarded and the pellets were resuspended in 1ml of raction. Each
fraction was then cultured separately in T-25 cm2 Flask until 80% confluence and finally, cells
from each fraction were dissociated by use of trypsin-EDTA, in Tcm2 Flask. Once
reached 80% confluence (about 40 days), cells from <15%, 15-25% and 25—35% fractions
could be frozen in liquid nitrogen or further passed for characterisation.
2014/077415
4. Characterization of the cells
Cells from <15%, 15-25% and 25-35% fractions were terized in number (cf. Point 4.1.),
for their clonogenic capacities (cf. Point 4.2.), for their abilities to differentiate into adipocytes,
chondrocytes and osteocytes when placed in adequate differentiation media (cf. Point 4.4.)
and for their expression of CD29, CD105, CD44, CD90, CD45 and MHC II with flux cytometry
(of. Point 4.3.). All of these tests were performed before and after freezing the cells in liquid
en. Cells from 15-25% and 25-35% fractions were also tested for their
immunomodulatory capacities (of. Point 5). Cells were also compared to Wharton’s jelly and
bone marrow MCSs for their expression miRNAs by RNA cing method (of. Points 6 to
8).
4.1. Number of cells
Once they were confluent, the number of cells contained in a T-175 cm2 Flask was evaluated
for each cell on.
4.2. Clonogenic capacity
The clonogenic capacities of the cells were evaluated with a "fibroblat—colony forming units"
assay (CFU-F). Cells from each fraction, in primo—culture or after one passage, were seeded
at low density (500000 flask) and grown for 10 days. May-Grunwald Giemsa staining was
used to visualise the colony forming units macroscopically and the total number of
colonies/flask were counted.
4.3. lmmunophenotyping
Harvested cells were analyzed by flow cytometry. Briefly, the cells (105) were washed with
PBS and incubated with the following monoclonal antibodies:
CD29-FITC (lmmunostep)
CD105-RPE (ABD c)
CD44-APC (BD gen)
MCH ll (ABD Serotec)
CD45-Alexa Fluor 488 (ABD Serotec)
CD90 (VMDR)
After washing with MACSQuant Running Buffer (Miltenyi Biotec), the cells were fixed with 4%
formaldehyde solution. Data were acquired using MACSQuant Analyzer and evaluated using
FCS Express 4 Flow Cytometry Software (De Novo Software, Los Angeles, CA, USA).
4.4. Multi-differentiation ial of cells
The differentiation potential of isolated cells was examined using cells harvested at P1 to P3.
Adipogenic, osteogenic, and chondrogenic differentiations were performed according to the
manufacturer’s instructions in adapted media (NH media, Miltenyi ).
- Adipogenic differentiation
For the adipogenic differentiation, 5000 cells/well were plated in a 24-well plate in NH
AdipoDiff Medium (Miltenyi Biotec). After 7, 14, and 21 days, cells were colored using Oil Red
0. Briefly, cells were washed with PBS and fixed with 8% formaldehyde before staining with
Oil Red 0 solution (Sigma).
- Chondrogenic entiation
To induce ogenesis, cells were transferred in the bottom of 15mL conical tubes and
differentiated into ocytes in pellet culture (250,000 cells/pellet) in 1mL specific
chondrocyte differentiation medium (NH ChondroDiff ; Miltenyi Biotec). Tubes were
incubated for 21 days at 37°C in a 5% C02 tor, and the medium was replaced every
week. Briefly, after 21 days, the micro-masses were fixed with methanol and whole mount
stained with alcian blue. Alcian blue was extracted with 6 mol/L guanidine hydrochloride and
absorbance was read at 620 nm.
- Osteogenic differentiation
For the osteogenic differentiation, the cells were plated in DM EM in a 24-well plate at a density
of 5,000 cells/well. After 24—48 h, the osteogenic medium (NH iff Medium; Miltenyi
Biotec) was added to the nt cells. Every week, cells were fed with complete
replacement of the medium. At days 7, 14, and 21, the calcium mineralization was assessed
by coloration with in Red (Sigma), as described by Meloan et al. with slight modifications.
Cells were washed in PBS and fixed in 70% ethanol at room temperature for 5 min followed by
several washes in H20. Cells were stained in 40mM Alizarin Red (Sigma) pH 4.2 for 15 min at
room temperature, rinsed in H20, and then air dried. Red staining was examined by light
microscopy.
The calcium accumulation was also measured (quantitative determination). To te
calcium deposition, the matrix was demineralized by addition of 200 pL of 0.6 N HCl and
overnight incubation at 37°C. Solutions were then collected and centrifuged at 2,000g for 5
min. Calcium concentration in the supernatant was determined by colorimetry (QuantiChrom
Calcium Assays Kit; BioAssay Systems) as described by the manufacturer. Briefly, 5 mL
s were combined with 200 mL calcium reagent and ted for 5 min at room
temperature. The absorbance was measured immediately after incubation at 610nm using a
plate reader (Organon Teknika Cappel Products).
2014/077415
. Evaluation of modulatory capacities of muscle-derived MSCs
CD2 T-lymphocytes (TL) were purified from blood of horses collected on EDTA tubes by using
magnetic beads. The CD2 TL population obtained showed a degree of purity of 99% (not
shown). The CD2 TL were then fluorescent marked with carboxyfluorescein succinimidyl ester
(CFSE), stimulated with phyto—hemagglutinin (PHA) and placed or not with the 15-25% or 25-
% fractions of the MSCs prepared by the method according to the present invention at
different ratios MSCs/CD2 TL: 4/1, 2/1, 1/1, 1/2, 1A; and 1/8. The inhibition of the CD2 TL
proliferation (%) provoked by the MSCs was evaluated by the change in fluorescence
observed and represents the immunomodulatory ties of the MSCs.
6. Isolation of mesenchymal stem cells from Wharton's jelly.
Horse cal cord segments (5—10 cm) were sectioned longitudinally to expose the
Wharton's jelly. Some incisions were made on the matrix with a sterile scalpel to expose a
wider area of tissue to contact with the plastic surface. The cord sections were then
transferred to a 10 cm2 Petri dish and plated for 5 days in Dulbecco’s modified Eagle’s
medium with 1.0 g/L glucose, without L-glutamine (DMEM; Lonza) supplemented with 15%
fetal bovine serum ), 2mM LGlutamine (Lonza), and 0.5% otic—antimycotic
solution (Lonza). Cultures were maintained in a humidified atmosphere with 5% C02 at 37°C.
After 5 days, the cord segments were discarded and the medium was renewed. The cells were
then expanded until they d subconfluence (BO—90%) with changing the medium every
week. At subconfluence, the cells were harvested after detachment by 10 min incubation with
TrprE Select solution (Lonza). For es, 5x104 cells were replated in 75 cm2 flask
(Falcon) in the same culture conditions until subconfluence. Cells were passaged until P4.
7. Isolation of bone marrow-derived mesenchymal stem cells.
Briefly, mononucleated cells (MNC) (from horse bone marrow s) were isolated by
density gradient fugation (LinfoSep; Biomedics, Madrid, Spain) and washed in HBSS
medium (Bio-Whittaker, Walkersville, MD). We seeded 0.5x106 cells/ml in alpha-minimum
essential medium (d-MEM; ttaker) supplemented with 15% FBS (Biochrom, Berlin,
Germany), 2 mM L-glutamine (GIBCO BRL, Grand Island, NY), 0.5% antibiotic/antimycotic
solution (GIBCO BRL). This is the complete d-MEM medium. MSCs, when selected by plastic
adhesion, require the ation of nonadherent cells by replacing the medium 48 hrs after
cell seeding. When es reached 80% confluence, cells were detached with trypsin-EDTA
solution (GIBCO BRL), and sub-cultured at 1x104 cells/ml.
8. Transcriptomic analysis
Method
The RNA sequencing (RNA-seq) method was used. Total RNA was extracted from 20 million
of MSCs prepared according to the method of the present invention (from the 15-25% fraction)
from 2 different horses, 20 million of n’s jelly stem cells from 1 horse and 20 million of
bone marrow derived stem cells from 1 horse using the RNAeasy mini kit (Qiagen). The cells
were lysed in RLT buffer containing beta-mercaptoethanol, then the RNA was purified on
column following manufacturer’s recommendations.
RNA integrity has been verified on Bioanalyser 2100 with RNA 6000 Nano chips, RIN scores
were >8 for all samples.
lllumina Truseq stranded mRNA Sample Preparation kit has been used to prepare librairies
from 1 microgram of total RNA. Poly-A RNAs were purified with coated magnetic beads
and chemically fragmented around 200 nucleotides. They are used as template for first strand
synthesis in the ce of random hexamers and second strand synthesis after. Next,
double strand cDNAs ends were adenylated at 3’OH extremities before the ligation to rs
containing the s. Finally, the adapters-ligated library fragments were enriched by PCR
following Illumina’s protocol and ed with Ampure XP magnetic beads. Libraries were
validated on Bioanalyser DNA 1000 chip and quantified by qPCR with the KAPA library
quantification kit. Sequencing has been performed on lllumina q500 in paired-end 2x75
base protocol.
Data analysis
Fastq files were d for adaptor ces. The reads were aligned with Tophat 2.0.9 to
the horse genome (Equus caballus (Horse) Eunab2 from UCSC). Cufflinks 2.2.0 suite was
used to generate FPKM values and CuffDiff was used to identify significantly differentially
expressed genes.
RESULTS
1. ng method
The microbiopsy technique allowed for the acquisition of a sufficient amount of horse muscular
tissue to easily initiate a culture. No contamination was observed, either during sampling or
treatment in the laboratory, thus validating our working conditions. As each microbiopsy was
cut into two pieces, it was possible to start two separate cultures with as little as 15-20 mg of
fissue.
2. Culture by explants
After three or four days in e, the first cells started to appear around the d muscle.
After about nine or ten days, the number of cells was sufficient for transplanting the explants
and let the cells grown alone (so-called 1st cells). The transplanting explants allowed us to
obtain a second pool of cells (so-called 2nd cells) that were also cultured till confluence. A
third pool of cells can also be obtained. Furthermore, the 2nd cells started to appear around
the piece of muscle faster than the 1st cells did.
3. Pluripotent stem cell isolation
For each 3 horses and in each Percoll fraction (i.e. <15%, 15-25%, 25-35%), we succeeded to
culture and to freeze an important amount of cells.
About 20 days after the initiation of the culture, the number of cells was sufficient to trypsinate
and start the isolation process. Before this process, we obtained 1.020.000 and 1.340.000 of
1st cells for horse 2 and horse 3, tively. The 2nd cells were 333.333 and 0 for
respectively horse 2 and horse 3.
4. Characterization of the cultured cells
4.1. Number of cells
4.2. Clonogenic capacity
' “5
—35%
«$152 3 M4}?r.%.>»
-” 5/
The morphological aspect of the CFU's observed was different of the ones habitually ed
with otent stem cells isolated from bone marrow or n’s Jelly (Figure 1).
In sections 4.1 and 4.2 above, P means “passage”; P1 is “passage1” and P2 is “passage 2”.
The term passage refers to “the transfer or subculture of cells from one culture vessel to
another; usually, but not necessarly, involves the subdivision of a proliferating cell population,
enabling the propagation of a cell line or cell strain.
The passage number is the number of times a e has been subcultured.
5. Immunophenotyping
The cells obtained were positive for CD44, CD90 and CD105 and negative for CD45, MHC II
and CD29. The cross vity of all these antibodies with horse has been checked on
mononucleated cells from equine bone marrows, except for CD29 (Figure 2 and 3).
For each of the three Percoll fractions, 85-95% of the cells expressed CD105 and > 90% of
them expressed CD44 and CD90 (Figure 3).
6. Multi-differentiation potential of cells
The cells obtained from each of the three Percoll fractions were able to differentiate into
adipocytes (Figure 4), ocytes (Figure 5) and osteocytes (Figure 6) when cultured with
the tive differentiation media.
7. Clinical use of cells
The horse MSCs obtained by the method according to the present invention are able to reduce
lameness and to e healing in horses affected by severe pathologies of the locomotor
system such as desmitis, tendonitis and osteoarthritis. The MSCs can be administrated either
directly in the lesions (tendon, ligament), or in the tendinous or articular synovials.
1/ lntratendinous injection of MSCs
A race horse (mare, 9 years old, thoroughbred) developed a severe tendonitis of the
superficial digital flexor tendon after a race. She received rest but no other treatment.
Three months after the injury she showed a grade I” left forelimb lameness, which was
positive to the lower limb and the carpal flexions. The diagnostic g examination
showed a postacute, healing superficial digital flexor tendon (SDFT) tendinopathy with
strong vascularisation and core lesion. The method according to the present invention
was used to obtain autologous MSCs from a muscular microbiopsy of the mare. A
control was made six weeks later. There was no significant improvement of the
lameness but the ultrasonographic examination showed a mild favorable evolution of
the left anterior SDFT healing and softness of the core lesion. The mare received
ultrasound-guided ion of 107 autologous MSCs in the core lesion of the SDFT.
She also received box g with 20 minutes walking/day. Six weeks later, the mare
showed a significant improvement of the left mb lameness. The ultrasonographic
examination was significantly , with an ed echogenicity (see table 1
below). The rehabilitation program is pursued.
A jumping horse (7 years old, Zangersheide, stallion) ped a right forelimb SDFT
tendonitis. He responded well to rest and NSAls (non-steroidal anti-inflammatory). He
returned to previous level of performance 4 months later but developed another palmar
swelling of the right forelimb after 3 weeks. He showed a grade III ss
ated to the swelling. The ultrasonographic examination showed a large
hypoechoic, 5*1*0.7cm, Doppler negative area with hyperechoic septa at the lateral
aspect of the SDFT in the distal third of the 3rd metacarpal bone. He received
corrective trimming, orthopedic shoeing and ultrasound-guided intralesional PrP
injection. A litation program was suggested. A ar microbiopsy was made
for the ation of MSCs according to the method of the present invention. The first
control took place 8 weeks later. The swelling was totally resorbed and a 2 stages
improvement of the lameness was noted. The ultrasonographic examination showed
an improvement as well: the lesion was less hypoechoic reduced by 2 (2.5*0.5*0.7cm)
with a better fibrillar aspect. The horse received ultrasound-guided injection of 107
autologous MSCs in the lesion of the SDFT. The rehabilitation program was pursued.
At the second control (2 months later), the horse showed no lameness at all and the
ultrasonography showed an ill-defined small hypoechoic area (see table 1 . The
horse received trimming, the orthopedic shoeing was maintained and the rehabilitation
program was d. At the last l (2 months after the second control), there
was no significant change in ultrasonographic images. The rehabilitation program was
ended and the orthopedic shoeing maintained.
2/ lntratendinous and intrasynovial injection of MSCs
- A leisure horse (gelding, 16 years old, half-blood) showed a grade III ss of the
left forelimb located below the fetlock. The imaging examination showed bilateral
anterior tendinopathy of the medial lobe of the deep digital flexor tendon (DDFT) and
light to mild degenerative joint disease of the left distal interphalageal joint.
Conventional intraarticular and orthopedic shoes were applied with no significant
improvement after 6 weeks. The method ing to the t invention was used
to obtain gous MSCs from a ar microbiopsy of the gelding. Four weeks
later, the horse received ultrasound-guided injection of 107 gous MSCs in the
medial lobe of the left anterior deep digital flexor tendon and in the corresponding
digital . The horse showed local moderate swelling on the injection site for 2
days after the stem cells stration. Six weeks later a control was performed
showing a mild improvement of the lameness and a light improvement of the
ultrasonographic images. The rehabilitation program was started and at the second
control, the horse was clearly better (see table 1 below). A progressive intensification
of the physical activity was proposed.
3/ lntraligamentar and intra-articular injection of MSCs
- A leisure pony (gelding, 5 years) affected by a severe desmitis of the lateral collateral
ligament of the right tarsocrural joint from 6 months and moderate signs of
degenerative joint disease. Lameness Ill/V, swollen joint, painful flexion with limited
range. tional treatments applied since the accident has not significantly
improved lameness. The method according to the present invention was used to
obtain autologous MSCs from a muscular microbiopsy of the pony. One month later, a
dose of 107 MSCs were injected in the ligament and 107 MSCs in the synovial pouch of
the tarso-crural joint. Six weeks later, a clinical improvement of the ss was
observed (grade l/V) with a clear decrease of the articular swelling and a normal
flexion (see table 1 below). A program of rehabilitation was prescribed and the pony
took over al activity.
Table 1: Effect of the injection at specific sites of autologous horse MSCs prepared
according to the method of the present ion (107/site of injection) on the lameness
score [from 0: absence of lameness to V: impossibility for the horse to use the affected
limb] of 4 horses with different osteo-articular diseases.
Diagnosis Site of injection ss Lameness ss
of autologous score before score after score after
MSCs injection (N) injection (N) 2"°' control
Case 1 Tendonitis lntratendineous III | 0
mare
9 yo.
thoroughbred
Case 2 Tendinopathy lntratendineous Ill 0 0
gelding and and ynovial
16 yo. degenerative
half-blood joint disease
Case 3 Desmitis and lntraligamentar III I 0
gelding degenerative and intra-
yo. joint disease articular
pony
Case 4 Tendonitis lntratendinous III | 0
stallion
7 yo.
Zangersheide
8. Immunomodulatory capacities of cells
An inhibition of the proliferation (%) of the horse CD2 T Lymphocytes (TL) was observed. For
the MSCs from the 15-25% fraction, the greater inhibition was observed with the ratio
MSCs/CD2 TL of 1/8. For the cells from the 25-35% fraction, the optimal ratio of D2
TL was 1/2 (see table 2 below).
Table 2: Inhibition of the proliferation (%) of the CD2 TL of 2 horses when ted
with MSCs from the 15-25% or the 25-35% fractions at different ratios MSCs/ CD2 TL (ie
4/1, 2/1, 1/1, 1/2, 1/4, 1/8).
Ratio MSCs 15-25%/CD2 TL
% inhibition of
CD2 TL
proliferation 4/1 2/1 1/1 1/2 1/4 1/8
Horse C 27 49 62 65 72 76
Horse Cbis 22 47 59 64 71 67
Horse D 0 17 27 28 38 40
MEAN 16,33 37,67 49,33 52,33 60,33 61,00
SEM 8,29 10,35 11,20 12,17 11,17 10,82
Ratio MSCs 25-35%ICD2 TL
% inhibition of
CD2 TL
proliferation 4/1 2/1 1/1 1/2 1/4 1/8
Horse C 32 55 72 67 73 72
Horse D 0 8 33 46 41 37
Horse Dbis 19 54 68 72 71 72
MEAN 17,00 39,00 57,67 61,67 61,67 60,33
SEM 9,29 15,50 12,39 7,97 10,35 11,67
9. Transcriptomic analysis - Differential expression of 5 miRNAs between horse MSCs
prepared according to the method of the present invention (abbreviated as muscle-
derived MSCs), horse n’s jelly MSCs and horse bone marrow MSCs.
We observed a significant differential expression for 56 genes between the 3 sources of stem
cells. We choose to focus on microRNAs (miRNA). 5 miRNA, namely 8, miR-1338,
miR—218, miR—656 and 2, showed a significant differential expression between the 3
s of stem cells. Probably because of the technique used, the miRNAs observed are the
precursors of the corresponding miRNA. From this experiment, it appears that miR—128 and
miR—133B were significantly overexpressed in muscle-derived MSCs compared to Wharton’s
jelly MSCs and bone marrow MSCs. miR—218 and 2 were also expressed by muscle-
derived MSCs but miR-218 was significantly higher expressed in bone marrow MSCS
compared to Wharton’s jelly MSCs and muscle-derived MSCs whereas miR—802 was
significantly overexpressed in the bone marrow MSCs and muscle-derived MSCs compared to
the Wharton’s jelly MSCs. miR—656 was significantly overexpressed in the Wharton’s jelly
MSCs ed to the bone marrow MSCs and muscle-derived MSCs (Figure 7).
ABBREVIATIONS
DF20: Growth culture medium composed of 12 with 20% fetal bovine serum, 5m|
penicillin (1000U/ml)—streptomycin (10000ug/ml), 2.5ml amphotericin B (250ug/ml) and 5m|
HEPES.
HBSS: Hank's balanced salt solution
REFERENCES
Adams, M.K., Goodrich, L.R., Rao, 8., OIea-Popelka, F., Phillips, N., Kisiday, J.D., Mcllwraith,
C.W. Equine bone marrow-derived hymal stromal cells (BMDMSCs) from the i|ium and
sternum: Are there differences? Equine nary Journal, 2012, 45, 372—375.
Ceusters J., Mouithys-Mickalad A., De La re De e G., Franck T., Votion D.,
Deby-Dupont G., Serteyn D. Assessment of reactive oxygen species production in cultured
equine skeletal myoblasts in response to conditions of anoxia followed by reoxygenation with
or without exposure to peroxidases. American Journal of Veterinary ch, 2012, 73, 426-
434.
Dominici, M., Le Blanc, K., Mueller, |., SIaper-Cortenbach, |., Marini, F., Krause, D., Deans, R.,
Keating, A., Prockop, D.J., Horwitz, E. l criteria for defining multipotent mesenchymal
stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy,
2006, 8(4), 315-317.
2014/077415
Gutierrez-Nibeyro, S.D. Commercial cell-based therapies for musculoskeletal injuries in
horses. Veterinary Clinics of North America: Equine Practice, 2011, 27, 363—371.
lacono, E, Brunori, L, Pirrone, A, ro, P, Ricci, F, Tazzari, PL, Merlo, B. ion,
characterization and differentiation of mesenchymal stem cells from amniotic fluid, umbilical
cord blood and Wharton’s jelly in the horse. Reproduction, 2012, 143, 455—468.
Meloan, S.N., er, H., Valentine, L.S. ne and acid in red S stains for alkalisoluble
and alkali-insoluble calcium deposits. Archives of Pathology, 1972,93(3),190-197.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman,
M.A., Simonetti, D.W., Craig, S., Marshak, D.R. ineage potential of adult human
mesenchymal stem cells (MSCs). Science, 1999, 284 (5411), 143-147.
, C.L., Nino—Fong, R., a Gonzalez, B.P., Stryhn, H., McDuffee, L.A.
Characterization and osteogenic potential of equine muscle tissue- and periosteal tissue-
derived mesenchymal stem cells (MSCs) in comparison with bone marrow- and e
tissue-derived mesenchymal stem cells (MSCs). American Journal of Veterinary Research,
2013,74(5), 790-800.
el L.V., Fortier L.A., Wayne Mcllwraith C., Nobert KM. Therapeutic use of stem cells in
horses: Which type, how, and when? The Veterinary Journal, 2013, 197(3), 570-577.
Usas,A., aitis, J., Maciulaitis, R., Jakuboniene, N., Milasius, A., Huard, J. Skeletal
muscle-derived stem cells: implications for cell-mediated therapies. Medicina (Kaunas), 2011,
47(9), 469-479.
Votion D.M., FraipontA., Goachet A.G., Robert C., Van Erck E., Amory H., Ceusters J., De La
Rebiere De Pouyade G., Franck T., Mouithys-Mickalad A., Niesten A., Serteyn D. Alterations
in mitochondrial respiratory function in response to endurance training and endurance racing.
Equine Veterinary Journal, 2010, 42(suppl 38), 268-274.
Claims (11)
1. A method for ing mammalian mesenchymal stem cells (MSCs) comprising the steps of: a) placing a microbiopsy from mammalian skeletal muscle tissue in suitable culture medium, b) collecting cells emerging from said microbiopsy during culturing, c) growing the cells obtained in step b) to near confluency, d) dissociating the cells from step c), and e) separating mesenchymal stem cells (MSCs) from the other cells by density nt fractionation, thereby obtaining mesenchymal stem cells (MSCs).
2. The method according to claim 1, n said mammal is selected from the group ting of: ic animals, farm animals, zoo animals, sport animals, pet animals, ion animals and experimental animals.
3. The method according to claim 2, wherein said mammal is selected from the group consisting of mice, rats, hamsters, rabbits, dogs, cats, guinea pigs, cattle, cows, sheep, horses, pigs and primates.
4. A mammalian mesenchymal stem cell population obtained by the method according to any one of claims 1 to 3, characterized by the following features: (i) that said cells express the CD105 antigen; (ii) that said cells additionally express CD44 and CD90; (iii) that said cells do not s the following s: CD45, MHC II and CD29; (iv) that said cells express at least one microRNA selected from the group consisting of miR-128 and miR-133B; (v) that said cells do not express the following microRNA: miR-656; and wherein the mesenchymal stem cells are capable of being differentiated into adipocytes, osteocytes, chondrocytes, myogenic cells, endothelial cells, neural cells, cardiac cells, and hepatocytes.
5. A pharmaceutical or veterinary composition comprising the mesenchymal stem cell tion according to claim 4 and a pharmaceutically acceptable excipient.
6. The hymal stem cell population according to claim 4, or the pharmaceutical or veterinary composition of claim 5, for use as a medicament or as a pharmaceutical or veterinary agent for treatment of one or more of the following disorders in a non-human mammalian subject: desmitis, osteochondrosis, arthritis, osteoporosis, tendonitis, laminitis, inflammation of the tendons and ligaments, fracture, and failure to heal.
7. The mesenchymal stem cell population for use according to claim 6, wherein autologous, allogeneic, or xenogenic mesenchymal stem cells (MSCs) are used.
8. Use of a mesenchymal stem cell population according to claim 4 or a pharmaceutical composition of claim 5 in the manufacture of a ment for the treatment of the following disorders in a human subject: desmitis, osteochondrosis, arthritis, osteoporosis, tendonitis, laminitis, inflammation of the s and ligaments, re, and e to heal.
9. The use according to claim 8, wherein the mesenchymal stem cell population is autologous, allogeneic, or xenogenic mesenchymal stem cells (MSCs).
10. The method according to claim 1 or 2, additionally comprising the step of differentiating the cells into ytes, osteocytes, chondrocytes, myogenic cells, endothelial cells, neural cells, cardiac cells, or hepatocytes by ing the MSCs in an adequate adipogenic, osteogenic, chondrogenic, myogenic, endothelial, neuronal, cardial, or hepatocytic differentiation medium respectively.
11. The method of claim 10, further sing the step of preparing a pharmaceutical or nary composition comprising the obtained differentiated adipocytes, osteocytes, chondrocytes, myogenic cells, endothelial cells, neural cells, cardiac cells or hepatocytes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13198477.5 | 2013-12-19 | ||
EP13198477 | 2013-12-19 | ||
PCT/EP2014/077415 WO2015091210A1 (en) | 2013-12-19 | 2014-12-11 | Mammalian muscle-derived stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ720440A NZ720440A (en) | 2021-10-29 |
NZ720440B2 true NZ720440B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2536366B (en) | Mammalian muscle-derived stem cells | |
Tsutsumi et al. | Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF | |
US20170290859A1 (en) | Novel Mensenchymal Stem Cells And Bone-Forming Cells | |
US20070243172A1 (en) | Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same | |
KR100871984B1 (en) | Multipotent Stem Cell Derived from Placenta Tissue and Cellular Therapeutic Agents Comprising the Same | |
TW201441369A (en) | MUSE cells isolation and expansion | |
JP7157896B2 (en) | Method for Obtaining Muscle-Derived Progenitor Differentiated Cells | |
JP5964956B2 (en) | Preparation of parent cell bank from fetal tissue | |
KR101760239B1 (en) | Method for isolating primary mesenchymal stem cells derived from human embryonic stem cells using cell insert culture system | |
Ninu et al. | Isolation, proliferation, characterization and in vivo osteogenic potential of bone-marrow derived mesenchymal stem cells (rBMSC) in rabbit model | |
JP2022189188A (en) | Method for producing mesenchymal stem cell | |
NZ720440B2 (en) | Mammalian muscle-derived stem cells | |
Joshi | Master of Veterinary | |
Mamoori et al. | DETECTION OF BETA-ACTIN AND OSTEOCALCIN GENES EXPRESSION IN DIFFERENTIATED OSTEOBLASTS BY RT-PCR | |
Radtke | An in vitro comparison of the osteogenic potential of equine stem cell populations and subpopulations from multiple tissue sources |